<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND &amp; AIMS: The exact incidence of <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> in patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE) is not known and is reported to vary from 0.2%-2% per year </plain></SENT>
<SENT sid="1" pm="."><plain>Published series of patients with BE have included relatively small numbers of patients with limited duration of follow-up </plain></SENT>
<SENT sid="2" pm="."><plain>The goal of this study was to define the prevalence and incidence of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and evaluate the paths of progression in a large multicenter cohort of BE patients </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: The BE study is a multicenter clinical and endoscopic outcomes project involving a single large database of patients with BE </plain></SENT>
<SENT sid="4" pm="."><plain>Data from each of the participating centers were merged into the main study database </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancers</z:e> and HGD occurring within 12 months of the index endoscopy were regarded as prevalent cases </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: One thousand three hundred seventy-six patients met the study criteria (95% white, 14% women); 91 patients had <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> at the initial endoscopy (prevalent cases, 6.7%; 95% confidence interval [CI], 4.8%-8.7%) </plain></SENT>
<SENT sid="7" pm="."><plain>Six hundred eighteen patients were followed for a total of 2546 patient-years; mean follow-up was 4.12 years </plain></SENT>
<SENT sid="8" pm="."><plain>Twelve patients developed <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> during follow-up, a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence of 1 in 212 patient-years of follow-up (0.5% per year; 95% CI, 0%-1.1%) </plain></SENT>
<SENT sid="9" pm="."><plain>The combined incidence of HGD and/or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> was 1 in 75 patient-years of follow-up or 1.3% per year (95% CI, 0%-2.2%) </plain></SENT>
<SENT sid="10" pm="."><plain>Of the 34 patients developing HGD and/or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, 18 patients (53%) had at least 2 initial consecutive endoscopies with biopsies revealing nondysplastic mucosa </plain></SENT>
<SENT sid="11" pm="."><plain>The incidence of LGD was 4.3% per year (95% CI, 2.8%-6.0%) </plain></SENT>
<SENT sid="12" pm="."><plain>In the 156 patients with LGD, regression to no <z:mpath ids='MPATH_589'>dysplasia</z:mpath> occurred in 66%, persistent LGD in 21%, and progression to HGD/<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in 13% </plain></SENT>
<SENT sid="13" pm="."><plain>The incidence of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in patients with LGD was 1 in 156 patient-years of follow-up or 0.6% per year (95% CI, 0%-1.3%) </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: Preliminary results from this trial define the prevalence and incidence of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in a multicenter cohort of patients with BE </plain></SENT>
<SENT sid="15" pm="."><plain>At least half the patients who developed HGD and/or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> had 2 consecutive initial endoscopies with biopsies revealing nondysplastic mucosa </plain></SENT>
<SENT sid="16" pm="."><plain>The majority of patients with LGD regressed and had a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence similar to <z:hpo ids='HP_0000001'>all</z:hpo> BE patients </plain></SENT>
</text></document>